Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Summary
The purpose of this phase I study is to evaluate the safety and feasibility of SX-682 in combination with Nivolumab in patients with metastatic adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.
General Information
NCT#: NCT04477343
Study ID: UGIP20027
Trial Phase: Phase I
Trial Sponsor: University of Rochester
Therapies Used in This Trial: Nivolumab, SX-682